Clinical Trial Update: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab [Phase 3]

View source ↗

Summary

Phase 3 trial assessing change in disease activity in adults with moderate-to-severe Ulcerative Colitis treated with risankizumab versus vedolizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Risankizumab (risankizumab)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING